Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal bupivacaine with or without intrathecal hydromorphone in gynecological laparotomy
NCT04258631Phase 4Completed
- Sponsor
- Mayo Clinic
- Start
- Jul 2020
- Primary completion
- Aug 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of hydromorphone in malignant female reproductive system neoplasm, sponsored by Mayo Clinic. Primary endpoint: Overall Benefit of Analgesia Score at 24 hours. Started Jul 2020; status: completed.
02
Drugs
hydromorphone
03
Conditions
malignant female reproductive system neoplasm
Beyond the preview
Go deeper on NCT04258631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04258631.